Tomas Philipson: By avoiding funding Alzheimer’s research, the government is cutting seniors’ life spans | The Chicago Tribune | 05/18/2023

By Tomas J. Philipson

Millions of patients and their caregivers breathed a collective sigh of relief when drugmaker Eli Lilly recently announced its new experimental Alzheimer’s medication appears to slow cognitive decline by 35%. The Food and Drug Administration could approve the new treatment, donanemab, as soon as this year.

It’s an encouraging development, but we’ll need more than a few cutting-edge drugs to reverse the future course of Alzheimer’s disease. According to the Alzheimer’s Association, 6 million Americans currently live with Alzheimer’s, and that number is projected to surpass 12.5 million by 2050.

Read the full article here.


Posted on

May 18, 2023

Scroll to Top